BioSpecifics Technologies Corp (BSTC) News

BioSpecifics Technologies Could Reverse on Topline Release http://marketexclusive.com/biospecifics-technologies-corp-nasdaqbstc-reverse-topline-release/6590/?icd1

$BSTC Daily and Weekly Charts

$BSTC Daily Chart

$BSTC DD Notes ~ http://www.ddnotesmaker.com/BSTC

bullish

$BSTC recent news/filings

## source: finance.yahoo.com

Tue, 21 Oct 2014 14:38:30 GMT ~ BIOSPECIFICS TECHNOLOGIES CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits


read full: http://biz.yahoo.com/e/141021/bstc8-k.html
*********************************************************

Tue, 21 Oct 2014 12:35:47 GMT ~ BioSpecifics Technologies Corp. Announces FDA Approval of sBLA for XIAFLEX® for the Concurrent Treatment of Two Dupuytren's Contracture Cords

[at noodls] - LYNBROOK, N.Y. , Oct. 21, 2014 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® (collagenase ...

read full: http://www.noodls.com/view/34A34CA8159524B277A2733F82BF5D0AEC01F886
*********************************************************

Tue, 21 Oct 2014 12:01:00 GMT ~ 8:01 am BioSpecifics Tech announces FDA approval of sBLA for XIAFLEX for the concurrent treatment of Two Dupuytren's Contracture Cords


read full: http://finance.yahoo.com/news/inplay-briefing-com-055139997.html#bstc
*********************************************************

Tue, 21 Oct 2014 12:00:00 GMT ~ BioSpecifics Technologies Corp. Announces FDA Approval of sBLA for XIAFLEX® for the Concurrent Treatment of Two Dupuytren's Contracture Cords

[PR Newswire] - LYNBROOK, N.Y., Oct. 21, 2014 /PRNewswire/ -- BioSpecifics Technologies Corp. (BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® (collagenase clostridium histolyticum or CCH) in the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) submitted by BioSpecifics' partner, Auxilium Pharmaceuticals, Inc. (Auxilium) for XIAFLEX for the treatment of up to two Dupuytren's contracture cords in the same hand during a single treatment visit. XIAFLEX obtained FDA approval in 2010 as the first and only nonsurgical treatment for adult Dupuytren's contracture patients with a palpable cord in the palm.

read full: http://finance.yahoo.com/news/biospecifics-technologies-corp-announces-fda-120000882.html
*********************************************************

Thu, 16 Oct 2014 13:25:07 GMT ~ BioSpecifics Technologies Corp. Announces Presentation of Encouraging Preclinical Data for CCH from Collaborative Uterine Fibroid Study with Duke Medicine

[at noodls] - LYNBROOK, N.Y. , Oct. 16, 2014 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® (collagenase ...

read full: http://www.noodls.com/view/3C0008303DB71FEE84E66A6011FDE7247DC54EDF
*********************************************************


$BSTC charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com


$BSTC company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/BSTC/company-info
Ticker: $BSTC
OTC Market Place: Not Available
CIK code: 0000875622
Company name: BioSpecifics Technologies Corp.
Company website: http://www.biospecifics.com
Incorporated In: DE, USA


$BSTC share structure

## source: otcmarkets.com

Market Value: $252,668,238 a/o Oct 22, 2014
Shares Outstanding: 6,477,012 a/o Aug 07, 2014
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.001
$BSTC extra dd links

Company name: BioSpecifics Technologies Corp.
Company website: http://www.biospecifics.com

## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/BSTC/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/BSTC/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=BSTC+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=BSTC+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=BSTC+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/BSTC/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/BSTC/news - http://finance.yahoo.com/q/h?s=BSTC+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/BSTC/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/BSTC/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/BSTC/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/BSTC/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/BSTC/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/BSTC/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/BSTC/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/BSTC/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=BSTC+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/BSTC
DTCC (dtcc.com): http://search2.dtcc.com/?q=BioSpecifics+Technologies+Corp.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=BioSpecifics+Technologies+Corp.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=BioSpecifics+Technologies+Corp.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.biospecifics.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.biospecifics.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.biospecifics.com

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/BSTC/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/BSTC
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/BSTC/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/BSTC/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/BSTC/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000875622&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/BSTC/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/BSTC/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/BSTC/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/BSTC/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=BSTC&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=BSTC
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/BSTC/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=BSTC+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=BSTC+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=BSTC
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=BSTC
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=BSTC+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/BSTC/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=BSTC+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/BSTC.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=BSTC
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/BSTC/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/BSTC/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/BSTC/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/BSTC/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/BSTC
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/BSTC
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/BSTC:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=BSTC
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=BSTC



$BSTC DD Notes ~ http://www.ddnotesmaker.com/BSTC

8:33AM BioSpecifics Tech announces positive top-line data from Phase 2 clinical trial of CCH for the treatment of human lipoma; primary efficacy outcome of active reduction of the visible surface area of the lipoma as measured by caliper was met (BSTC) 21.83 :

Co announced top-line data from the Phase 2 dose escalation clinical trial of collagenase clostridium histolyticum (CCH) for the treatment of human lipoma. Lipomas are benign fatty tumors that usually present as painful or palpable lumps in the subcutaneous tissues. The primary efficacy outcome of active reduction of the visible surface area of the lipoma as measured by caliper was met, combining all patients (p<0.0001). There were no serious adverse events reported during the trial.
"Based on the results from both studies reported to date, we intend to initiate a placebo-controlled study to further assess the efficacy and safety of CCH for the treatment of human lipoma in the first half of 2014. We also plan to explore the potential to expand CCH into new pipeline indications with unmet medical needs this year."
BioSpecifics' strategic partner Auxilium Pharmaceuticals (AUXL) has the option to exclusively license development and marketing rights to the human lipoma indication following completion of a new trial, which would trigger an opt-in payment and potential future milestone and royalty payments from Auxilium.

8:32AM BioSpecifics Tech announces top-line data from Phase 2 trial of CCH for canine lipoma; trial did not meet its primary endpoint of a statistically significant post-treatment difference in the mean percent change in lipoma volume by CT scan; however, in the responder analysis there was a statistically significant reduction in lipoma surface area among dogs treated with CCH (p=0.0084) (BSTC) 21.79 :

Co announced top-line data from Chien-804, the placebo-controlled, double-blind, randomized Phase 2 trial evaluating the efficacy of collagenase clostridium histolyticum (CCH) in canines with benign subcutaneous lipomas. Lipomas are encapsulated deposits of fat often detected as bulges under the skin and affect an estimated 1.7 million dogs in the U.S. The trial did not meet its primary endpoint of a statistically significant post-treatment difference in the mean percent change in lipoma volume by CT scan; however, in the responder analysis there was a statistically significant reduction in lipoma surface area among dogs treated with CCH (p=0.0084).
Chien-804 enrolled 37 dogs in a single injection study randomized 1:1 CCH to placebo with lipoma volume being measured by CT scan and lipoma surface area being measured by caliper at baseline, one month and 90 days. The data at 90 days show a post-treatment difference in the mean percent change in lipoma volume by CT scan between the CCH and placebo-treated groups of -11.58% (p=0.52), which was not statistically significant. The percent change at 90 days in mean visible surface area measured by caliper showed a difference of -24.18% (p=0.09), which approached statistical significance. Among those dogs whose lipomas decreased by 50%, the results achieved statistical significance and showed that the visible surface area as measured by caliper decreased by 50% or more in 47.4% of CCH-treated dogs (9 out of 19) versus 5.9% of placebo-treated dogs (1 out of 17), with a p-value of 0.0084. A questionnaire administered to pet owners, while blinded to the study, showed 84.2% satisfaction with the results of CCH treatment versus 33.4% satisfaction with the placebo results (p=0.005).

8:04AM BioSpecifics Tech announces XIAFLEX progress in two pipeline indications; FDA accepts supplemental biologics license application filing for treatment of Peyronie's Disease (BSTC) 14.53 : Co announced progress for XIAFLEX in two pipeline indications. BioSpecifics' strategic partner Auxilium Pharmaceuticals has exercised its exclusive option under the Second Amended and Restated Development and License Agreement, dated as of August 31, 2011, to expand the field of its license for injectable collagenase to include the potential treatment of adult patients with edematous fibrosclerotic panniculopathy, commonly known as cellulite. As a result, BioSpecifics will receive a license fee payment of $500,000 from Auxilium. In addition, on December 27, 2012, the U.S. Food and Drug Administration (FDA) accepted for filing Auxilium's supplemental Biologics License Application (sBLA) for XIAFLEX for the potential treatment of Peyronie's disease. As a result, BioSpecifics will also receive a modest milestone payment from Auxilium. The filing was granted standard review status and, under the Prescription Drug User Fee Act (PDUFA), the FDA is expected to take action on the application by September 6, 2013.

7:57AM On The Wires (WIRES) : BioSpecifics Technologies (BSTC) has initiated a placebo controlled randomized Phase II clinical trial, Chien-804, to evaluate the efficacy of XIAFLEX for canines with benign subcutaneous lipomas.

BioSpecifics Tech BSTC Stifel Nicolaus Buy $29

~ Monday! $BSTC ~ Earnings posted, pending or coming soon! In Charts and Links Below!

~ $BSTC ~ Earnings expected on Monday *
Want more like this? Search Keyword: MACMONEY >>> http://tinyurl.com/MACMONEY <<<
One or more of many earnings sites has alerted this security has or will be posting earnings on or around the day of this message.








http://stockcharts.com/h-sc/ui?s=BSTC&p=D&b=3&g=0&id=p88783918276&a=237480049




http://stockcharts.com/h-sc/ui?s=BSTC&p=W&b=3&g=0&id=p54550695994



~ Google Finance: http://www.google.com/finance?q=BSTC
~ Google Fin Options: hhttp://www.google.com/finance/option_chain?q=BSTC#
~ Yahoo! Finance ~ Stats: http://finance.yahoo.com/q/ks?s=BSTC+Key+Statistics
~ Yahoo! Finance ~ Profile: http://finance.yahoo.com/q/pr?s=BSTC
Finviz: http://finviz.com/quote.ashx?t=BSTC
~ BusyStock: http://busystock.com/i.php?s=BSTC&v=2


<<<<<< http://www.earningswhispers.com/stocks.asp?symbol=BSTC >>>>>>



http://investorshub.advfn.com/boards/post_prvt.aspx?user=251916

*If the earnings date is in error please ignore error. I do my best.

6:29AM BioSpecifics Tech. confirms FDA approval of XIAFLEX for treatment of Dupuytren's contracture (BSTC) 27.00 : Co confirms the FDA has approved XIAFLEX, a novel, first-in-class, orphan-designated, biologic, for the treatment of adult Dupuytren's contracture patients with a palpable cord. Dupuytren's contracture is a debilitating disease resulting from excessive collagen deposition that causes contractures of the fingers.

Graduated from OTCBB to NASDAQ

01/09/2009 BSTC >> BSTC BioSpecifics Technologies Corp. Common Stock NGM 124,641,121

http://www.otcbb.com/dynamic/tradingdata/daily/graduations.htm